Bicarbonate/lactate dialysis solution improves in vivo function of peritoneal host defense in rats

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Pawlaczyk, Krzysztof ^a   Kuzlan Pawlaczyk, Malgorzata ^a   Wieczorowska Tobis, Katarzyna ^a   Polubinska, Alicja ^a   Wisniewska, Justyna ^a   Faict, Dirk ^b   Holmes, Cliff J ^c   Breborowicz, Andrzej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Baxter Europe   (Belgium)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Bicarbonate; Cytokines; Inflammation; Peritoneal permeability

Indexed keywords

BICARBONATE; CYTOKINE; DIALYSIS FLUID; ENDOTOXIN; GAMMA INTERFERON; GLUCOSE; LACTIC ACID; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL COUNT; CONFERENCE PAPER; CONTROLLED STUDY; HOST RESISTANCE; MACROPHAGE; MALE; MEMBRANE PERMEABILITY; NEUTROPHIL; NONHUMAN; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PH; PRIORITY JOURNAL; RAT;

EID: 0033397285     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s60     Document Type: Conference Paper

References (32)

1. Liberek T, Topley N, J̈orres A, Coles GA, Gahl GM, Williams JD. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993; 65:260-5.
2. Douvdevani A, Rapoport J, Konforty A, Yulzari R, Moran A, Chaimovitz C, et al. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol. 1995; 6:207-13.
3. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cells and interleukin-6 and prostaglandin synthesis. Kidney Int. 1995; 47:282-93.
4. Breborowicz A, Rodela H, Martis L, Oreopoulos DG. Intracellular glutathione in human peritoneal mesothelial cells exposed in vitro to dialysis fluid. Int J Artif Organs. 1996; 19:268-75.
5. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int. 1997; 17:42-9.
6. Dobos GJ, Bohler J, Kuhlmann J, Elsner J, Andre M, Passlick-Deetjen J, et al. Bicarbonate-based dialysis solutions preserve granulocytes functions. Perit Dial Int. 1994; 14:366-70.
7. Sundaram S, Cendoroglo M, Cooker LA, Jaber BL, Faict D, Holmes CJ, et al. Effect of two-chambered bicarbonate lactate buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis. 1997; 30:680-9.
8. Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, et al. Biocompatibility of bicarbonate-buffered peritoneal dialysis fluids: Influence on mesothelial cells and neutrophils function. Kidney Int. 1996; 49:1447-56.
9. Kristensen SR, Pedersen FB. Cytotoxicity testing of two CAPD dialysis fluids in a model system of quiescent fibroblasts. Nephrol Dial Transplant. 1993; 8:163-7.
10. Cooker LA, Lunenburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int. 1997; 17:373-8.
11. Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, et al. Bicarbonate-versus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int. 1992; 12:281-6.
12. Gotloib L, Wajsbrot V, Shostack A, Kushnier. Experimental approach to peritoneal morphology. Perit Dial Int. 1994; 14(Suppl 3):S6-11.
13. Di Paolo N, Garosi G, Petrini G, Traversari L, Rossi P. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int. 1995; 15(7, Suppl):S61-70.
14. Yatzidis H. Enhanced ultrafiltration in rabbits with bicarbonate glycylglycine peritoneal dialysis solution. Perit Dial Int. 1993; 13:302-6.
15. Wieczorowska-Tobis K, Korybalska K, Polubinska A, Radkowski M, Breborowicz A, Montagne A, et al. Long-term effects of glycylglycine peritoneal dialysis solution with neutral pH on peritoneum in rats. In: Khanna R, ed. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1997; 13:42-6.
16. Yamamoto T, Sakakura T, Yamakawa M, Horiuchi N, Hirata S, Iritani Y, et al. Clinical effect of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron. 1992; 60:324-9.
17. Holmes CJ, Topley N, Kaur D, et al. A biocompatibility comparison of bicarbonate-versus bicarbonate/lactate-based solutions for peritoneal dialysis [Abstract]. J Am Soc Nephrol. 1994; 5:414.
18. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int. 1998; 53:1061-7.
19. Mackenzie RK, Holmes CJ, Moseley A, Jenkins J, Williams JD, Coles GA, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFα secretion. J Am Soc Nephrol. 1998; 9:1499-506.
20. Jones S, Williams JD, Holmes CJ, Mackenzie R, Coles GA, Faict D, et al. Bicarbonate/lactate-buffered peritoneal dialysis fluid decreases procollagen I and transforming growth factor-β1 levels in peritoneal dialysis effluent [Abstract]. Perit Dial Int. 1998 18(Suppl 2):S83.
21. Wieczorowska-Tobis K, Korybalska K, Polubinska A, Radkowski M, Breborowicz A, Oreopoulos DG. In vivo model to study the biocompatibility of peritoneal dialysis solutions. Int J Artif Organs. 1997; 20:673-7.
22. Lowry OH, Rosenbrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem. 1951; 193:265-75.
23. Gillian MB, Sherman MP, Griscavage JM, Ignarro LJ. A spectrophotometric assay for nitrate using NADPH oxidation by aspergillus nitrate reductase. Anal Biochem. 1993; 212:359-65.
24. Duwe AK, Vas SI, Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun. 1981; 33:130-5.
25. Jörres A. Is introduction of the bicarbonate buffer in PD solution unavoidable? Perit Dial Int. 1996; 16:444-5.
26. de Fijter CW, Verbrugh HA, Peters ED, Oe PL, van der Meulen J, Verhoef J, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol. 1993; 39:75-80.
27. Bos HJ, Struijk DG, Tuk CW, de Veld JC, Helmerhorst TJ, Hoefsmit EC, et al. Peritoneal dialysis induces a local sterile inflammatory state and the mesothelial cells in the effluent are related to the bacterial peritonitis incidence. Nephron. 1991; 59:508-9.
28. Brulez HFH, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int. 1995; 15(7, Suppl):S24-34.
29. Topley N, Mackenzie R, Petersen MM, Beavis MJ, Williams D, Thomas N, et al. In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant. 1991; 6:574-81.
30. Dasgupta MK, Larabie M, Halloran PF. Interferon-gamma levels in peritoneal dialysis effluents: Relation to peritonitis. Kidney Int. 1994; 46:475-81.
31. Lamperi S, Carozzi S. Interferon-gamma as in vitro enhancing factor of peritoneal macrophage defective bactericidal activity during continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1988; 11:225-30.
32. Calame W, Hendrickx RJBM, Namavar F, Beelen RH. Effect of interferon-γ in dialysis fluid on peritoneal defence in rats. Nephrol Dial Transplant. 1995; 10:1212-17.